English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Recombinant Adenovirus serotype 5 (Ad5) vectors have been used as vaccine platforms to induce cell mediated and humoral immune responses in human clinical studies. The immune response induced by Ad5 vaccines can be mitigated due to pre-existing Ad5 immunity. The Ad5 [E1, E2b-] platform is an Ad5 vector with novel deletions in the Ad5 DNA polymerase and the preterminal protein genes contained in the E2b region. This vector has been reported to allow for induction of potent immune responses to transgene antigens in the presence of Ad5 immunity. This vector expressing a tumor associated antigen is now advancing to clinical evaluation as a cancer therapeutic agent. We previously reported the use of the Ad5 [E1-, E2b-] platform to induce cellular immune responses (CMI) against HIV-1 Gag in Ad5 hyper immune mice.

P19-47. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity